Panmure Gordon disclosed Sphere Medical Holding PLC (LON:SPHR), retaining its price target at 17.00GBX earlier today
- Updated: September 21, 2016
Reporting as potential upside of 0.36%, Panmure Gordon hold steady the price target of Sphere Medical Holding PLC (LON:SPHR) at 17.00GBX
On 9/15/2016, Panmure Gordon released a statement on Sphere Medical Holding PLC (LON:SPHR) maintained the target price at 17.00GBX that suggested an upside of 0.33%.
Having a price of 12.50GBX, Sphere Medical Holding PLC (LON:SPHR) traded 2.40% higher on the day. With the last close up 16.38% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. SPHR has recorded a 50-day average of 11.37GBX and a two hundred day average of 11.00GBX. Volume of trade was up over the average, with 108,433 shares of SPHR changing hands over the typical 75,934
See Chart Below
Sphere Medical Holding PLC has a 52 week low of 6.00GBX and a 52 week high of 15.00GBX The company’s market cap is currently 0 GBX.
General Information About Sphere Medical Holding PLC (LON:SPHR)
Sphere Medical Holding plc is engaged in the development of medical monitoring and diagnostic equipment. The Company operates through medical devices segment. The Company is engaged in the manufacture and sale of products within the medical device area. The Company's products include Proxima and Pelorus. Proxima is a patient-connected blood gas and electrolyte solution for managing patient pathways. Proxima is an in-line patient arterial blood analyzer, which supports measurements at critical times. Its products are used in intensive care (ICU) and operating room (OR) environments to provide physicians with data to help them make clinical decisions for their patients. Its products and systems help in a range of medical situations, including blood gas monitoring and analysis, propofol sedation and total intravenous anesthesia (TIVA). The Company has operations in the United Kingdom, Germany, the Netherlands and Belgium.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.